Payment overview · 2025
General Payments
$1,756.56
100 reported records · 21 companies
Healthcare provider profile · identity verified
Ashley Glover Shuffield, MD
Allopathic & Osteopathic Physicians|Family Medicine · MAUMELLE, AR · NPI 1508328253
Verified facts
What the public records show
CMS Open Payments records show Ashley Glover Shuffield, MD received $1,756.56 in general payments during 2025 across 100 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $317.69 | 18.1% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $293.69 | 16.7% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $190.45 | 10.8% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.70 | 10.5% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.95 | 7.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $107.24 | 6.1% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.25 | 5.4% | 5 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $72.70 | 4.1% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.93 | 3.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.99 | 2.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.70 | 2.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $39.77 | 2.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.46 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.05 | 1.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.29 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.77 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.37 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.21 | 1.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.13 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.32 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $12.90 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,756.56 | 100 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $222.76 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $171.76 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.08 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.84 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.00 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.89 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $106.74 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.25 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.59 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.73 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $87.17 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.66 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.38 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.38 | 5 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $72.70 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.93 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.81 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.99 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $12.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 197 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 38 |
| Omeprazole | Omeprazole | 145 | 33 |
| Lisinopril | Lisinopril | 127 | 28 |
| Gabapentin | Gabapentin | 107 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 23 |
| Losartan Potassium | Losartan Potassium | 94 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 23 |
| Metformin Hcl | Metformin Hcl | 64 | 19 |
| Simvastatin | Simvastatin | 62 | 19 |
| Montelukast Sodium | Montelukast Sodium | 60 | 14 |
| Metformin Hcl Er | Metformin Hcl | 57 | 13 |
| Meloxicam | Meloxicam | 56 | 18 |
| Bupropion Xl | Bupropion Hcl | 49 | 15 |
| Potassium Chloride | Potassium Chloride | 49 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Carvedilol | Carvedilol | 48 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 20 |
| Trazodone Hcl | Trazodone Hcl | 47 | 20 |
| Ondansetron Odt | Ondansetron | 45 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 14 |
| Furosemide | Furosemide | 44 | 14 |
| Ozempic | Semaglutide | 44 | 11 |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 11 |
| Famotidine | Famotidine | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Prednisone | Prednisone | 31 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Latanoprost | Latanoprost | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,756.56 · 100 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, EVENITY, GARDASIL 9, GEMTESA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SPRAVATO, Sunosi, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error